

DRUG ALERT
CLASS 4 MEDICINES DEFECT INFORMATION

Caution in Use
Distribute to Pharmacy and Wholesaler Level

Dear Healthcare Professional

Strathclyde Pharmaceuticals Ltd

**Xarelto 20 mg film-coated tablets
(Rivaroxaban)**


EU/1/08/472/018

Batch Number	Expiry Date	Pack Size	First Distributed
BXHHDR1	09/2019	28 tablets	18/09/2017

Brief description of the problem

Strathclyde Pharmaceuticals Ltd has received a report of a rogue blister strip of 15 mg tablets within two packs of 20 mg tablets and has decided to recall this batch. The labelling on one side of the blister strips reflects the correct strength of the tablets as shown:

MPS 2494
MMS 1841



Xarelto® 20 mg film-coated tablets
rivaroxaban
28 film-coated tablets **EU/1/08/472/018**

Each film-coated tablet contains 20 mg rivaroxaban.
Contains lactose. See package leaflet for further information.
For oral use. Medicinal product subject to medical prescription.
Read the package leaflet before use.
Keep out of the sight and reach of children.
Marketing Authorisation Holder: Bayer AG, 51368 Leverkusen, Germany.
Manufacturer: Bayer AG, Kaiser-Wilhelm-Allee, 51368 Leverkusen, Germany.
Parallel distributed by: Strathclyde Pharmaceuticals Ltd,
East Kilbride, G75 0TD, UK.
Re-packaged by: Munro Wholesale Medical Supplies Ltd,
East Kilbride, G75 0TD, UK.
Batch: BXHHDR1 EXP: 09.2019 Re-pack: 040500
Xarelto® is a registered trade mark of Bayer Aktiengesellschaft

PKG472018-3(G)

UK
IRELAND
MALTA
POM

Advice for healthcare professionals

Please take the following actions:

- Quarantine any remaining stock from batch BXHHDR1 and return it to the original supplier.
- Identify patients or carers that have received Strathclyde Pharmaceuticals Ltd Xarelto 20 mg tablets (including in compliance aids) since the 18 September 2017 inclusive.
- Contact these patients or carers to notify them of this issue and to ask them whether the tablets have batch BXHHDR1 printed on any of the packaging.
- Ask patients or carers who have received batch BXHHDR1 to check if any of the blisters or tablets are labelled as 15 mg.
- If the patient or carer finds any of the blisters or tablets labelled as 15 mg, they should be asked to return the tablets to the pharmacy where they were purchased or dispensed. If the tablets and blisters inside the carton are the correct strength of 20 mg, patients or carers do not need to return the tablets to the pharmacy.
- If the patient or carer does have tablets of the incorrect strength, make sure that you provide new supplies of this medicine from other batches. It is important for patients not to interrupt their treatment unless instructed by healthcare professionals.
- If patients have been dispensed Strathclyde Pharmaceuticals Ltd Xarelto 20 mg tablets in compliance aids since 18 September 2017 inclusive, patients or carers should be asked to return the compliance aids to the pharmacy in order to be issued with replacements.
- **Wholesalers**
- Wholesalers are requested to return any remaining stock of batch BXHHDR1 to their original supplier for credit.

- **Patients**
- If you have received any Xarelto (rivaroxaban) 20 mg tablets since the 18 September 2017 inclusive, please check if BXHHDR1 is printed on any of the packaging.
- If BXHHDR1 is printed anywhere on the packaging, check if there are any tablets or blisters in the carton labelled 15 mg. If so, please speak to your healthcare professional as soon as possible about obtaining a replacement pack.
- It is important that you do not interrupt your treatment unless instructed by healthcare professionals.
- If you have been dispensed Xarelto (rivaroxaban) 20 mg tablets in compliance aids (containers with all the medication for each day of the week) since 18 September 2017 inclusive, please return all your compliance aids to the pharmacy in order to be issued with replacements.
- If you experience side-effects, or have any questions or concerns about your health, speak to your doctor, pharmacist, or other healthcare professional. Any suspected side effects can be reported to MHRA through our medicines safety monitoring system, the [Yellow Card Scheme](#) or download the Yellow Card App [here](#).
- **Medical information enquiries** For medical information enquiries please contact Julie Cummings on 01355 574450.
- **Stock enquiries** For stock enquiries please contact Shirley Gorrell on 01355 574450.

Recipients of this Drug Alert should bring it to the attention of relevant professionals by copy of this letter.

TO ALL CHEMISTS, DOCTORS ON THE LISTS

Pharmaceutical Services
2 Franklin Street
BELFAST
BT2 8DQ

Telephone No. 028 9536 3552
Fax No. 028 9536 3901

2nd October 2017

Pharmaceutical website: <http://www.hscbusiness.hscni.net>